

2723534

# ASTRAZENECA PLC

## Interim Financial Statements

30 JUNE 2003



EDX  
COMPANIES HOUSE  
COMPANIES HOUSE

\*E00TF88Y\*

0815  
21/7/03  
07/08/03

Registered number : 2723534

# ASTRAZENECA PLC

## PROFIT AND LOSS ACCOUNT

for the six months ended 30 June 2003

	Notes	Six months to 30 June 2003 \$m	Year ended 31 Dec 2002 \$m
Turnover		-	-
Operating costs		(4)	(9)
<b>Operating loss</b>		<b>(4)</b>	<b>(9)</b>
Income from shares in subsidiary undertakings		-	5
<b>Loss on ordinary activities before interest</b>		<b>(4)</b>	<b>(4)</b>
Net interest and exchange gains / (losses)	2	218	153
<b>Profit on ordinary activities before taxation</b>		<b>214</b>	<b>149</b>
Taxation		(64)	(47)
<b>Net profit for the period/year</b>		<b>150</b>	<b>102</b>
Dividends to Shareholders	3	(436)	(1,206)
<b>Loss retained for the period / year</b>		<b>(286)</b>	<b>(1,104)</b>

## STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES

for the six months to 30 June 2003

There are no gains or losses other than those reported above and therefore a statement of recognised gains and losses has not been presented.

# ASTRAZENECA PLC

## BALANCE SHEET

as at 30 June 2003

	Notes	30 June 2003 \$m	31 Dec 2002 \$m
<b>Fixed Assets</b>			
Fixed asset investments	4	6,940	7,236
		6,940	7,236
<b>Current assets</b>			
Debtors		26,282	27,104
		26,282	27,104
<b>Total assets</b>		33,222	34,340
<b>Creditors due within one year</b>			
Short-term borrowings		(4)	(3)
Other creditors		(2,410)	(2,958)
		(2,414)	(2,961)
<b>Net current assets</b>		23,868	24,143
<b>Total assets less current liabilities</b>		30,808	31,379
<b>Creditors due after more than one year</b>			
Loans		(295)	(295)
		(295)	(295)
<b>Provisions for liabilities and charges</b>		-	-
<b>Net assets</b>		30,513	31,084
<b>Capital and reserves</b>			
Called-up share capital	5	428	429
Share premium account	6	428	403
Capital redemption reserve	6	18	16
Other reserves	6	1,841	1,841
Profit and loss account	6	27,798	28,395
<b>Shareholders' fund – equity interests</b>		30,513	31,084

The financial statements on pages 1 to 5 were approved by the Board of Directors on 24<sup>th</sup> July 2003 and were signed on its behalf by:



Sir Tom McKillop  
Director



Jonathan Symonds  
Director

# ASTRAZENECA PLC

## NOTES RELATING TO THE FINANCIAL STATEMENTS

### 1 Basis of presentation of financial information

The AstraZeneca PLC accounts are presented in accordance with the accounting policies set out in the 2002 annual accounts.

### 2 Net interest and exchange gains / (losses)

	Six months to 30 June 2003 \$m	Year ended 31 Dec 2002 \$m
<b>Interest payable and similar charges</b>		
Payable to subsidiary undertakings	(20)	(41)
Net exchange gains/(losses)	40	(12)
	20	(53)
<b>Interest receivable and similar income</b>		
Receivable from subsidiary undertakings	198	206
	198	206
<b>Net interest and exchange gains / (losses)</b>	218	153

# NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

## 3 Dividends to Shareholders

	Six months to 30 June 2003 cents per 25c Share	Year ended 31 Dec 2002 cents per 25c Share	Six months to 30 June 2003 \$m	Year ended 31 Dec 2002 \$m
1 <sup>st</sup> interim	25.5c	23c	436	398
2 <sup>nd</sup> interim/final	-	47c	-	808
	25.5c	70c	436	1,206

## 4 Fixed Asset Investments

	Shares \$m	Loans \$m	Total \$m
<b>Cost or valuation</b>			
At beginning of period	6,645	591	7,236
Additions	-	-	-
Disposals	-	-	-
Other – reclassification	-	(296)	(296)
<b>Cost or valuation and net book value at end of period</b>	6,645	295	6,940

## 5 Called-up share capital

	Authorised 30 June 2003 \$m	Allotted, called-up and fully paid	
		30 June 2003 \$m	31 Dec 2002 \$m
Ordinary Shares (\$0.25 each)	428	428	429
Unissued Ordinary Share (\$0.25 each)	172	-	-
Redeemable Preference Shares (£50,000)	-	-	-
	600	428	429

The movements in share capital during the period are summarised as follows:

	No of shares (million)	\$m
At beginning of period	1,719	429
Issue of shares	1	1
Repurchase of shares	(9)	(2)
At 30 June 2003	1,711	428

# NOTES RELATING TO THE FINANCIAL STATEMENTS (continued)

## 6 Reserves

	Share Premium Account	Capital Redemption Reserve	Other Reserves	Profit and Loss Account	Total Six months to 30 June 2003	Year ended 31 Dec 2002
	\$m	\$m	\$m	\$m	\$m	\$m
At beginning of period	403	16	1,841	28,395	30,655	32,873
Net profit for the period	-	-	-	150	150	102
Dividends	-	-	-	(436)	(436)	(1,206)
Share repurchase	-	2	-	(311)	(309)	(1,183)
Share premiums	25	-	-	-	25	69
At end of period	428	18	1,841	27,798	30,085	30,655
Distributable reserves at end of period	-	-	468	1,842	2,310	2,057

At 30 June 2003, \$25,956m (31 December 2002 \$26,781m) of the profit and loss account reserve was not available for distribution. The majority of this non-distributable amount relates to profit arising on the sale of Astra AB to a subsidiary in 1999, which becomes distributable as the underlying receivable is settled in cash. During the period, \$825m of the profit was realised by repayment. Subsequent to the period end a further \$924m was repaid on 18<sup>th</sup> July 2003 resulting in additional distributable reserves not included in the figures above. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

## 7 Reconciliation of Movements in Shareholders' Funds

	Six months to 30 June 2003 \$m	Year ended 31 Dec 2002 \$m
Net profit for the financial period / year	150	102
Dividends	(436)	(1,206)
	(286)	(1,104)
Issues of AstraZeneca Ordinary Shares	26	69
Repurchase of AstraZeneca Ordinary Shares	(311)	(1,190)
Net reduction/addition to shareholders' funds	(571)	(2,225)
Shareholders' funds at beginning of period / year	31,084	33,309
Shareholders' funds at end of period / year	30,513	31,084